Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After football on WRAL: Patchy fog to start the school year. Where your kids will be likely to see it at the bus stop.
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ovid Therapeutics Inc
(NQ:
OVID
)
1.210
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
203,265
Open
1.210
Bid (Size)
0.9900 (1)
Ask (Size)
1.230 (40)
Prev. Close
1.210
Today's Range
1.185 - 1.220
52wk Range
0.6800 - 4.100
Shares Outstanding
70,417,345
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
August 19, 2024
Via
Benzinga
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-63.55%
-63.55%
1 Month
+14.15%
+14.15%
3 Month
-60.33%
-60.33%
6 Month
-67.12%
-67.12%
1 Year
-69.01%
-69.01%
More News
Read More
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 13, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
The Latest Analyst Ratings For Ovid Therapeutics
July 26, 2024
Via
Benzinga
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
June 18, 2024
Via
Benzinga
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
August 01, 2024
From
The Schall Law Firm
Via
Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 30, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 23, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Via
InvestorPlace
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 10, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
July 01, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
June 17, 2024
Via
Benzinga
Is the Stock Market Closed on Juneteenth 2024?
June 17, 2024
Via
InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
June 17, 2024
Via
InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
June 17, 2024
Via
InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
June 17, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
June 17, 2024
Via
Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
June 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Mixed; Dow Tumbles Over 100 Points
June 17, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
Via
Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
June 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 17, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.